Follow The Filings

IDYA IDEAYA Biosciences

IDEAYA Biosciences earnings company data as of 7:49 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 3 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by IDYA's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IDYA insider trades
  • $1.6M bought by 1 insider
  • None no sales outside a trading plan
  • $1.4M sold by 2 insiders under 10b5-1 plans
  1. Yujiro S Hata CEO
    Planned sale
    $985K 26,338 shares at $37.41 3.7% of stake
    Traded Oct 6 Filed Oct 8
    ↗
  2. Briseno Andres Ruiz Chief Accounting Officer
    Planned sale
    $382K 9,550 shares at $40.01 27% of stake
    Traded Jul 7 Filed Jul 9
    ↗
  3. Jeffrey Stein Director
    Buy
    $1.6M 50,000 shares at $32.96 +1168% to stake
    Traded Mar 2 Filed Mar 2
    ↗

Also filed in the last 12 months, not counted as buying or selling: 2 stock grants and 2 option exercises.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
SCHEDULE 13G — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07,8.01 Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
8-K 8.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
DEFA14A Filing Doc
DEF 14A Filing Doc
8-K 8.01 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.